- Home
- ROIV vs IONS Comparison
ROIV vs IONS Comparison
Compare ROIV & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- IONS
- Stock Information
- Founded
- ROIV 2014
- IONS 1989
- Country
- ROIV United Kingdom
- IONS United States
- Employees
- ROIV N/A
- IONS N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ROIV Health Care
- IONS Health Care
- Exchange
- ROIV Nasdaq
- IONS Nasdaq
- Market Cap
- ROIV 7.8B
- IONS 6.9B
- IPO Year
- ROIV N/A
- IONS 1991
- Fundamental
- Price
- ROIV $11.85
- IONS $43.78
- Analyst Decision
- ROIV Buy
- IONS Buy
- Analyst Count
- ROIV 3
- IONS 14
- Target Price
- ROIV $15.25
- IONS $58.43
- AVG Volume (30 Days)
- ROIV 4.5M
- IONS 2.0M
- Earning Date
- ROIV 08-11-2025
- IONS 07-30-2025
- Dividend Yield
- ROIV N/A
- IONS N/A
- EPS Growth
- ROIV N/A
- IONS N/A
- EPS
- ROIV N/A
- IONS N/A
- Revenue
- ROIV $23,233,000.00
- IONS $944,050,000.00
- Revenue This Year
- ROIV $3.28
- IONS $9.21
- Revenue Next Year
- ROIV $156.84
- IONS $14.35
- P/E Ratio
- ROIV N/A
- IONS N/A
- Revenue Growth
- ROIV N/A
- IONS 16.05
- 52 Week Low
- ROIV $8.73
- IONS $23.95
- 52 Week High
- ROIV $13.06
- IONS $50.43
- Technical
- Relative Strength Index (RSI)
- ROIV 58.16
- IONS 60.61
- Support Level
- ROIV $10.90
- IONS $40.37
- Resistance Level
- ROIV $12.12
- IONS $41.93
- Average True Range (ATR)
- ROIV 0.30
- IONS 1.42
- MACD
- ROIV 0.03
- IONS -0.03
- Stochastic Oscillator
- ROIV 77.87
- IONS 66.61
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.